We have not explained this story yet. The original headline, summary and link are below.

Pfizer distributed $48.8 billion in dividends and buybacks over the last five years, yet its stock experienced a total return of -16.8% during the same period, significantly underperforming the S&P 500. This paradox highlights the challenge for mature, profitable companies to generate shareholder value when growth lags, emphasizing the importance of a strong R&D pipeline to sustain long-term growth and justify capital return policies. Investors are left questioning whether generous payouts compensate for a declining stock value without future growth drivers.